# HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

> **NCT06375317** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yehua Shen** · enrollment: 42 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets

## Key facts

- **NCT ID:** NCT06375317
- **Lead sponsor:** Yehua Shen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375317, "HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06375317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*